Three biotechs priced upsized IPOs in a single window, totaling more than $850 million combined, and moved into public trading with gains in the aftermarket. Seaport Therapeutics, Hemab Therapeutics, and Avalyn Pharma collectively marked a strong reopening of the IPO channel for biotech investors. Seaport’s launch followed its listing strategy shift, with Puretech choosing to exit the market for a London Stock Exchange-only posture while Seaport raised gross proceeds of $254.9 million. Hemab priced a larger-than-expected deal, targeting coagulation disorders including Glanzmann thrombasthenia and von Willebrand disease, and set gross proceeds at $301.5 million. Hypergrowth in the sector was also reflected in related deals outside the IPO bucket: Hypervision Surgical raised £17 million for an AI-enabled hyperspectral imaging platform intended to provide surgeons real-time tissue physiology insights. The net effect is fresh risk capital flowing into both clinical-stage and technology-enabled life sciences, suggesting sustained appetite for differentiated platforms and commercially addressable therapeutic areas even amid volatile equity conditions.